[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"WOM World Of Medicine AG\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":53},{"warningLetters":4,"total":52},[5,30],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},21696,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-23T04:00:00Z\">09\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonline-generic-medicinewwwonlinegenericmedicinecom-737806-09232026\">Online Generic Medicine\u002Fwww.onlinegenericmedicine.com\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drug\u002FMisbranded (Internet Pharmacy)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Online Generic Medicine\u002Fwww.onlinegenericmedicine.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 23, 2026\u003Cbr>\u003Cbr>info@onlinegenericmedicine.com\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: MARCS-CMS 737806\u003C\u002Fp>\u003Cp>To Online Generic Medicine:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, FDA has observed that www.onlinegenericmedicine.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\u003C\u002Fp>\u003Cp>Accordingly, FDA requests that www.onlinegenericmedicine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website www.onlinegenericmedicine.com, FDA Establishment Identifier (FEI) 3048678145, on August 26, 2026, and September 2, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On your website at internet address www.onlinegenericmedicine.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.onlinegenericmedicine.com are drugs within the meaning of section 201(g) of the FD&amp;C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You failed to obtain approved applications pursuant to section 505 of the FD&amp;C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved semaglutide drug product you offer for sale on www.onlinegenericmedicine.com is semaglutide marketed as \"Semanat Injection (Semaglutide).\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanat Injection, [sic] is a potent glucagon-like peptide-1 (GLP-1) receptor agonist wich [sic] is designed to help manage blood sugar levels in type 2 diabetes and support weight management.\"\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for \"Semanat Injection (Semaglutide)” offered by www.onlinegenericmedicine.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\u003C\u002Fp>\u003Cp>\u003Cem>Misbranded Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&amp;C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering this drug for sale to U.S. consumers, www.onlinegenericmedicine.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.onlinegenericmedicine.com jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&amp;C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737806” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, PharmD\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nOnline Generic Medicine\u002Fwww.onlinegenericmedicine.com\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 23, 2026\n\ninfo@onlinegenericmedicine.com\nWARNING LETTER\nReference Number: MARCS-CMS 737806\nTo Online Generic Medicine:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, FDA has observed that www.onlinegenericmedicine.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\nAccordingly, FDA requests that www.onlinegenericmedicine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nFDA Review\nViolations were identified and documented during a review of your website www.onlinegenericmedicine.com, FDA Establishment Identifier (FEI) 3048678145, on August 26, 2026, and September 2, 2026.\nViolations of the Federal Food, Drug, and Cosmetic Act\nOn your website at internet address www.onlinegenericmedicine.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nCertain products offered for sale by www.onlinegenericmedicine.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.\nYou failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.\nAn example of an unapproved semaglutide drug product you offer for sale on www.onlinegenericmedicine.com is semaglutide marketed as \"Semanat Injection (Semaglutide).\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanat Injection, [sic] is a potent glucagon-like peptide-1 (GLP-1) receptor agonist wich [sic] is designed to help manage blood sugar levels in type 2 diabetes and support weight management.\"\nWhile there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for \"Semanat Injection (Semaglutide)” offered by www.onlinegenericmedicine.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\nFDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\nFDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\nFurthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\nMisbranded Drug Violations\nA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nYou failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.onlinegenericmedicine.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.\nFurthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.onlinegenericmedicine.com jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737806” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, PharmD\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Online Generic Medicine\u002Fwww.onlinegenericmedicine.com","online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonline-generic-medicinewwwonlinegenericmedicinecom-737806-09232026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-06","737806","Drugs","2026-10-14T12:33:20.472+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-09-23",{"id":31,"raw":32,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},2143,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-14T04:00:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023\">Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FIRB ","Bioresearch Monitoring Program\u002FIRB","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert J. Hayashi, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>660 South Euclid Avenue, Box 8116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63110-1010\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref.: 23-HFD-45-03-02\u003Cbr>\n\u003Cbr>\nDear Dr. Hayashi:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, of investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>requires that you omit certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatments for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigational plan for Protocol&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\u003C\u002Fp>\n\n\u003Cp>1. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that you omit administration of Day 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the final 2 cycles of maintenance therapy for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> was a pediatric subject (5 years old) randomized to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, this subject was administered 12 mg of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on \u003Cstrong>(b)(6)\u003C\u002Fstrong>, respectively. As a result, this subject underwent invasive procedures associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an increased risk of infection associated with lumbar punctures.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\u003C\u002Fp>\n\n\u003Cp>You also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Day 1 of Cycles 5 and 6 for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reinforcing the need to calculate the end of therapy and when the last administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong> administration, and that training on these SOPs was provided.\u003C\u002Fp>\n\n\u003Cp>2. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires an \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the initiation of any cycle of 3-day interval of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>) administration. If this treatment eligibility criterion is not met, the 3-day course of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not initiated. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> had a calculated \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(6)\u003C\u002Fstrong>; however, this subject received a 3-day course of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on Days 1 to 3 of Cycle 3 (\u003Cstrong>(b)(6)\u003C\u002Fstrong>). Thus, you failed to ensure that the only enrolled subject in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong>, met the required treatment eligibility criterion before the administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\u003C\u002Fp>\n\n\u003Cp>As described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\u003C\u002Fp>\n\n\u003Cp>Additionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational \u003Cstrong>(b)(6)\u003C\u002Fstrong> agent; (2) the creation of procedural SOPs for \u003Cstrong>(b)(6)\u003C\u002Fstrong> ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong>, with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (4) good clinical practice training.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n03\u002F14\u002F2023 07:42:17 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert J. Hayashi, M.D.\n\nRobert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\n\n660 South Euclid Avenue, Box 8116\n\nSaint Louis, MO 63110-1010\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef.: 23-HFD-45-03-02\n\nDear Dr. Hayashi:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\n\nProtocol (b)(4), “(b)(4),” of the investigational drug (b)(4), performed for the (b)(4)\n\nProtocol (b)(4), “(b)(4), of investigational drug (b)(4) performed for the (b)(4)\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nYou failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\n\nAs a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) requires that you omit certain (b)(4) treatments for subjects randomized into the (b)(4). In addition, the investigational plan for Protocol (b)(4) requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\n\n1. The investigational plan for Protocol (b)(4) requires that you omit administration of Day 1 (b)(4) during the final 2 cycles of maintenance therapy for subjects randomized into the (b)(4). Subject (b)(6) was a pediatric subject (5 years old) randomized to the (b)(4); however, this subject was administered 12 mg of (b)(4) on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on (b)(6), respectively. As a result, this subject underwent invasive procedures associated with (b)(4) administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered (b)(4) are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with (b)(4), and an increased risk of infection associated with lumbar punctures.\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of (b)(4) and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\n\nYou also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove (b)(4) from Day 1 of Cycles 5 and 6 for (b)(4), in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive (b)(4).\n\nFurthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol (b)(4), reinforcing the need to calculate the end of therapy and when the last administration of (b)(4) is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for (b)(6) ordering, to minimize errors in (b)(6) administration, and that training on these SOPs was provided.\n\n2. The investigational plan for Protocol (b)(4) requires an (b)(4) before the initiation of any cycle of 3-day interval of (b)(4) ((b)(4)) administration. If this treatment eligibility criterion is not met, the 3-day course of (b)(4) ((b)(4)) is not initiated. Subject (b)(6) had a calculated (b)(4) on (b)(6); however, this subject received a 3-day course of (b)(4) ((b)(4)) on Days 1 to 3 of Cycle 3 ((b)(6)). Thus, you failed to ensure that the only enrolled subject in Protocol (b)(4), Subject (b)(6), met the required treatment eligibility criterion before the administration of (b)(4).\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an (b)(4) for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\n\nAs described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\n\nAdditionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational (b)(6) agent; (2) the creation of procedural SOPs for (b)(6) ordering, to minimize errors in (b)(6), with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of (b)(4); and (4) good clinical practice training.\n\nWe acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\n\nWe emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n03\u002F14\u002F2023 07:42:17 AM","Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics","robert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-10-26T08:09:50.433203+00:00","2023-03-28","654873","Robert J. Hayashi, M.D.","2026-08-20T01:10:40.684+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-03-14",2,{"510k":54,"classification":55,"enforcement":56,"event":57,"event_backfill":58,"pma":59,"warning_letter":60},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]